Systemic therapy should be considered in patients with advanced non–small cell lung
cancer (NSCLC) who are no longer amenable to local therapies. Systemic therapy has been …

Background: Lung cancer is the second most common cancer in the United States among
men and women, and it is the most common cause of cancer-related death. Non–small cell …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Introduction: The discovery of new actionable oncogenic drivers has led to the development
of effective antineoplastic targeted agents in advanced non-small cell lung cancer (NSCLC) …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Lung adenocarcinoma is the most common subtype of lung cancer today. With the discovery
of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) …

Lung cancers are broadly divided into small-cell lung cancer (SCLC) and non-SCLC
(NSCLC), and the treatments for each differ. NSCLC includes squamous cell carcinoma …

Simple Summary The use of novel therapeutic drugs in lung cancer has changed the
paradigm of the diagnosis and treatment of lung cancer. Due to the development of …

Over the last decade, systemic cancer therapies have evolved to exploit the growing
knowledge of molecular aberrations involved in the development and progression of lung …

Lung cancer is the most common malignancy in the US and causes the most cancer-related
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …